RAPP Rapport Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why RAPP matters now
Rapport Therapeutics, Inc. Common Stock (RAPP) is a US stock in Healthcare. The latest InvestLog snapshot shows $41.75 with -0.71% on the session and $1.52B in market capitalization; recent performance reads 1-month +8.64% and YTD +23.07%.
The latest financial table shown here is Q1 2026, with revenue of $20.0M, net income of $-19.9M, and EPS of $-0.42. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.9%.
The latest indexable market news headline is "Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $60.50; recent insider activity includes Sanchez Ramiro filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.74
P/S
68.14
EV/EBITDA
-10.97
DCF Value
$0.79
FCF Yield
-5.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.0%
Operating Margin
-611.0%
Net Margin
-536.4%
ROE
-24.8%
ROA
-21.6%
ROIC
-25.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.0M | $-19.9M | $-0.42 |
| Q4 2025 | $0.00 | $-33.8M | $-0.72 |
| FY 2025 | $0.00 | $-111.5M | $-2.86 |
| Q3 2025 | $0.00 | $-26.9M | $-0.71 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$57.50
Target (Median)
$60.50
Target Range
$43.00 - $66.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.98
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.